INTRODUCTION
============

The *Escherichia coli*AcrB multidrug efflux pump is a membrane protein that recognizes many chemically unrelated compounds including various dyes and antibiotics and expels them in collaboration with the so called membrane fusion protein AcrA and the outer membrane protein TolC which are both needed for function. The pump belongs to the resistance-nodulation-division (RND) family of efflux pumps that are common in gram-negative microorganisms. Based on various X-ray crystallographic, mutagenic and biochemical studies the tripartite efflux pump AcrAB-TolC is one of the best characterized bacterial efflux pumps \[[@R1]-[@R10]\]. It is also the only RND pump in *E. coli* that contributes significantly to antibiotic resistance against clinically relevant antibiotics due to its constitutive expression. Exposure to antimicrobial agents can further increase efflux-mediated resistance due to mutations in the *acrR* or *marR* gene leading to upregulation of the efflux pump \[[@R11]\]. Since the above mutations can relatively rapidly be selected by exposure to only one antibiotic and since the substrate spectrum of AcrAB-TolC is so large, generation of multidrug resistance via efflux of antimicrobial compounds is a real threat to treatment options in the clinic.

Since the antimicrobial drug pipeline is relatively empty -- especially against gram-negatives -- efflux pump inhibitors (EPIs) that revert multidrug resistance are an attractive target. Interestingly, several working groups have recently described psychotropic drugs, namely phenothiazines \[[@R12],[@R13]\] and selective serotonine reuptake inhibitors (SSRIs) \[[@R14]\] that are capable of inhibiting the AcrAB-TolC efflux pump in *E. coli.* By screening more psychotropic drugs we discovered that the neuroleptic drug pimozide is also a model efflux pump inhibitor.

MATERIALS AND METHODS
=====================

Bacterial Strains and Growth Conditions
---------------------------------------

*E. coli* strains 3-AG100 (a multidrug-resistant mutant (*gyrA* *marR*) with *acrB* overexpression obtained from *E. coli* K-12 strain AG100 after repeated exposure to a fluoroquinolone) and the *acrB* knockout strain 1-DC14 \[[@R15]\] were grown in LB broth (1% tryptone, 0.5% yeast extract, and 1% NaCl), or on LB agar (1.5%) plates (Roth, Karlsuhe, Germany).

Chemicals
---------

All chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany). Since pimozide is poorly soluble in water it was dissolved in hot lactic acid (0.03 %).

Susceptibility Testing
----------------------

The MICs of a range of antimicrobial agents in the presence and absence of pimozide were determined in a 96-well microtiter plate using strains incubated overnight at 37°C in a volume of 100µl/well by a standard LB broth microdilution procedure and a final inoculum of 5 X 10^5^ CFU/ml. MIC testing was done in triplicate. Custom 96-well microtiter plates containing selected antimicrobials at increasing concentrations were purchased from Merlin Diagnostics (Bornheim, Germany).

RESULTS
=======

Fluorescence Assays
-------------------

The protocols for the Nile red efflux \[[@R16]\] and ethidium bromide (EtBr) accumulation \[[@R17]\] assay have been published previously. The only modification was that the standard 20 mM potassium phosphate buffer (pH 7) amended with 1 mM MgCl~2~ used in the Nile red efflux assay was also used in the ethidium bromide accumulation assay. Moreover, the EtBr concentration was increased to 10 µM.

Using AcrAB-TolC overproducing strain 3-AG100 pimozide at concentrations of up to 200 µM did not reduce the MIC of the following antibiotics: tetracycline, chloramphenicol, rifampicin, and linezolid (Table **[1](#T1){ref-type="table"}**). Oxacillin MICs were reduced twofold at 200 µM but not at 100 µM. The levofloxacin MICs behaved somewhat paradoxical with twofold reduction at 100 µM but no reduction at 200 µM.

Adding the dye EtBr to the MIC panel, we determined that EtBr MICs were reduced 4-fold. The intrinsic MIC for pimozide was found to be \> 1000 µM, whereas in the AcrB-deficient strain 1-DC14 it was 100 µM.

Nile Red Efflux and EtBr Accumulation Assays
--------------------------------------------

Notable retardation of Nile red efflux in strain 3-AG100 was observed in the presence of pimozide at a threshold concentration of 25 µM (Fig. **[1](#F1){ref-type="fig"}**). Adding higher concentration of pimozid led to increasing efflux retardation in a dose-dependent manner. At 100 µM Nile red efflux was almost completely abolished.

Adding the pimozide just 50 s before energization yielded the same results. Controls with 0.03 % lactic acid and no pimozide did not alter the substrate efflux.

In line with these observations, 100 µM pimozide led also to a pronounced increase in EtBr accumulation that was even stronger than 100 µM carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP) (Fig. **[2](#F2){ref-type="fig"}**).

DISCUSSION
==========

In the Nile red efflux and EtBr accumulation assays the neuroleptic drug pimozide behaved like an EPI, in the case of Nile red comparable to Phe-Arg-β-naphthylamine (PAßN) \[[@R18]\]. However, the effect in the MIC assays was generally much less pronounced. Only in the case of EtBr could a fourfold reduction in MIC be observed. It thus seems that the effect of pimozide is highly substrate-specific. Such behaviour has been described before in the well-studied EPI PAßN. Although this EPI potentiates the activity of a wide variety of antimicrobial compounds it fails to do so with ethidium bromide \[[@R19]\]. As recently suggested by molecular docking \[[@R20]\] and X-ray crystallographic \[[@R8]\] studies we hypothesize that the observed discrepancy is mainly due to different EPI and substrate binding sites so that the activity of a given EPI might be highly substrate specific. It seems that pimozide is an extreme case in this regard since we could only demonstrate that it interferes with the transport of EtBr and Nile red but not with a range of clinically relevant antimicrobials.

While this observation and the fact that the plasma peak levels of this drug required for EPI activity cannot be safely reached in humans preclude its clinical usefulness, we suggest that pimozide can still be valuable as a "narrow-spectrum" model EPI to learn more about substrate -- EPI interactions.
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![Dose-dependent Nile red efflux inhibition in 3-AG100 in the presence of pimozide (*ΔacrB* strain 1-DC14 used for comparison). Addition of glucose (final concentration 50 mM) 50 seconds into the experiment to trigger efflux.](TOMICROJ-7-83_F1){#F1}

![Effect of pimozide on EtBr accumulation in the acrAB-overexpressing strain 3-AG100 (*ΔacrB* strain 1-DC14 used for comparison). Pimozide or CCCP were added 50 seconds and EtBr (final concentration 10 µM) 500 seconds into the experiment. 50 mM glucose was present in the buffer throughout the assay.](TOMICROJ-7-83_F2){#F2}

###### 

Synergy of Pimozide with Selected Antibacterial Drugs and Ethidium in *E. coli.*

  Strain                                                                                                                                                                                                                                                                                                                                                                       
  --------- -------- --------------------------------------- -------------------- -------- -------------------- -------------------- -------- -------------------- -------------------- -------- -------------------- -------------------- -------- -------------------- -------------------- -------- -------------------- -------------------- -------- -------------------- --------------------
            No EPI   \+ pimozide 100 µM                      \+ pimozide 200 µM   No EPI   \+ pimozide 100 µM   \+ pimozide 200 µM   No EPI   \+ pimozide 100 µM   \+ pimozide 200 µM   No EPI   \+ pimozide 100 µM   \+ pimozide 200 µM   No EPI   \+ pimozide 100 µM   \+ pimozide 200 µM   No EPI   \+ pimozide 100 µM   \+ pimozide 200 µM   No EPI   \+ pimozide 100 µM   \+ pimozide 200 µM
  3-AG100   2        1                                       2                    4        4                    4                    16       16                   16                   16       16                   16                   512      256                  256                  1024     1024                 1024                 512      256                  128
  1-DC14    0.125    n.g. [a](#T1F1){ref-type="table-fn"})   n.g.                 0.5      n.g.                 n.g.                 1        n.g.                 n.g.                 4        n.g.                 n.g.                 0.5      n.g.                 n.g.                 16       n.g.                 n.g.                 8        n.g.                 n.g.

no growth.
